Shanghai Haohai Biological Tech Co (688366 SHG) stock market data APIs

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. The company offers ophthalmology products consisting intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. It also offers sodium hyaluronate injection, medical chitosan, sodium hyaluronate gel, sodium hyaluronate gel, anti adhesion, and burn wound related products. In addition, the company provides injectors, scalpels, and suture needles. Further, it offers medical aesthetics products comprising Matrifill, a first-generation hyaluronic acid (HA) dermal filler, which is a mono-phase sodium hyaluronate gel for injection; Janlane, a second-generation HA dermal filler for dynamic filling function; Hyalumatrix, a third-generation HA dermal filler that offers precise embellishment function; genetic-engineering preparations for epidermal repair; and radio frequency devices and laser equipment. Additionally, the company is involved in the research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services; sale of professional life and home cosmetology machines; and manufacture and sale of biological reagents, biologicals and biological materials, and other machines and accessories. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.